DE69333751D1 - Nicht-verbreitendes lebendes herpesvirusvakzin - Google Patents

Nicht-verbreitendes lebendes herpesvirusvakzin

Info

Publication number
DE69333751D1
DE69333751D1 DE69333751T DE69333751T DE69333751D1 DE 69333751 D1 DE69333751 D1 DE 69333751D1 DE 69333751 T DE69333751 T DE 69333751T DE 69333751 T DE69333751 T DE 69333751T DE 69333751 D1 DE69333751 D1 DE 69333751D1
Authority
DE
Germany
Prior art keywords
vaccine
pct
pseudorabies virus
mutant
live
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69333751T
Other languages
English (en)
Other versions
DE69333751T2 (de
Inventor
Nicolaas Visser
Woensel Alphonsus Van
Christoph Mettenleiter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of DE69333751D1 publication Critical patent/DE69333751D1/de
Publication of DE69333751T2 publication Critical patent/DE69333751T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/265—Infectious rhinotracheitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16721—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DE1993633751 1992-07-30 1993-06-28 Nicht-verbreitendes lebendes herpesvirusvakzin Expired - Fee Related DE69333751T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP92202370 1992-07-30
EP92202370 1992-07-30
PCT/EP1993/001661 WO1994003595A1 (en) 1992-07-30 1993-06-28 Non-shedding live herpesvirus vaccine

Publications (2)

Publication Number Publication Date
DE69333751D1 true DE69333751D1 (de) 2005-03-10
DE69333751T2 DE69333751T2 (de) 2005-12-29

Family

ID=8210818

Family Applications (1)

Application Number Title Priority Date Filing Date
DE1993633751 Expired - Fee Related DE69333751T2 (de) 1992-07-30 1993-06-28 Nicht-verbreitendes lebendes herpesvirusvakzin

Country Status (7)

Country Link
US (1) US5626850A (de)
EP (1) EP0606437B1 (de)
JP (1) JPH07500972A (de)
AT (1) ATE288483T1 (de)
AU (1) AU4560693A (de)
DE (1) DE69333751T2 (de)
WO (1) WO1994003595A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0561034B1 (de) 1991-08-26 1999-06-09 IMMUNO Aktiengesellschaft Direkt molekuläre Klonierung eines modifizierten Genoms eines Chordopocken-Virus
TW289731B (de) * 1992-07-09 1996-11-01 Akzo Nv
US7223411B1 (en) 1992-07-31 2007-05-29 Dana-Farber Cancer Institute Herpesvirus replication defective mutants
US5612215A (en) * 1992-12-07 1997-03-18 Ribozyme Pharmaceuticals, Inc. Stromelysin targeted ribozymes
EP0689603A1 (de) * 1993-03-19 1996-01-03 Cantab Pharmaceuticals Research Limited Defektiver mutanter nicht-retroviraler virus (2.b.hsv) zum impstoff
EP0659885A1 (de) * 1993-12-21 1995-06-28 Akzo Nobel N.V. Impstoffe gegen von Antikörper abhängende Vergrösserung (ADE) der Virus-Infektivität
WO1995030018A2 (en) * 1994-04-29 1995-11-09 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions
EP0693551A1 (de) 1994-07-18 1996-01-24 Akzo Nobel N.V. gD-Negative Rinder-Herpesvirus Mutanten, mit der Fähigkeit zur direkten Zell zu Zell Übertragung
GB9415369D0 (en) * 1994-07-29 1994-09-21 Lynxvale Ltd Mutant virus
WO1996026267A1 (en) * 1995-02-21 1996-08-29 Cantab Pharmaceuticals Research Limited Viral preparations, vectors, immunogens, and vaccines
DE19626614A1 (de) * 1996-07-02 1998-01-08 Immuno Ag Komplex aus Antigen und Zellbestandteil, Impfstoffzusammensetzung, welche den Komplex enthält, pharmazeutische Präparation sowie Verfahren zur Herstellung des Komplexes
US6399354B1 (en) 1998-07-31 2002-06-04 President And Fellows Of Harvard College Replication-competent virus expressing a detectable fusion protein
KR100774066B1 (ko) 1999-09-29 2007-11-06 신에쯔 한도타이 가부시키가이샤 웨이퍼, 에피택셜웨이퍼 및 이들의 제조방법
CN103468645B (zh) * 2013-08-30 2016-08-10 北京中联康生物科技股份有限公司 伪狂犬病毒、伪狂犬病疫苗及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005263A1 (en) * 1990-09-25 1992-04-02 Cantab Pharmaceuticals Research Limited Viral defective vaccine produced by transcomplementing cell line
US5240703A (en) * 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof

Also Published As

Publication number Publication date
WO1994003595A1 (en) 1994-02-17
DE69333751T2 (de) 2005-12-29
EP0606437B1 (de) 2005-02-02
EP0606437A1 (de) 1994-07-20
JPH07500972A (ja) 1995-02-02
AU4560693A (en) 1994-03-03
ATE288483T1 (de) 2005-02-15
US5626850A (en) 1997-05-06

Similar Documents

Publication Publication Date Title
DE69333751D1 (de) Nicht-verbreitendes lebendes herpesvirusvakzin
Bagust et al. Avian infectious laryngotracheitis: Virus‐host interactions in relation to prospects for eradication
GB9105383D0 (en) An immunotherapeutic for cervical cancer
TW289731B (de)
Martin et al. Mechanisms of antiviral immunity induced by a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: cytotoxic T cells
Jameson et al. Diversity in T cell memory: an embarrassment of riches
BR9708387A (pt) Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
ES8505719A1 (es) Procedimiento de preparar mutantes de delecion vivos y metodo de preparar vacunas
ATE219948T1 (de) Rekombinante impfstoffe die immunogene attenuierte rpos-positiv phentotyp bakterien enthalten
ATE239036T1 (de) Rekombinantes core-streptavidin
IL77694A (en) Canine parvovirus vaccines comprising viruses of the canine parvovirus strain 154 or viruses derived therefrom by additional cell culture passaging
HUP0105430A2 (hu) Attenuált baktériumok, alkalmazásuk, továbbá a baktériumokat tartalmazó vakcinák
IL103144A0 (en) Method of controlling lepidopteran pests
DE69929530D1 (de) Attenuierte pferdeherpesvirus
DE69332264T2 (de) Mutanten des infektiösen rinder rhinotracheitis-virus und impfstoffe
YU49995A (sh) Polinukleotidna vakcina za virus herpesa
Hill The immune response to CMV infection and vaccination in mice, monkeys and humans: recent developments
ATE178654T1 (de) Impstoff zum schutze von pferden gegen pferdeherpesvirus-infektionen
ATE263837T1 (de) Expressionsteigerung durch gentargeting in endogene retrovirus-ähnliche sequenzen
AU1853995A (en) Vaccine compositions
ES2074965A1 (es) Virus mutante recombinante de rinotraqueitis infecciosa bovina y vacunas que lo contienen.
Grabstein et al. Regulation of Murine B-Cell Growth in Vitro by Infection with a Retroviral Vector Containing the Murine IL-1R
Morris et al. The presence of an inhibitor of human skin collagenase in the roots of healthy and periodontally diseased teeth.
NO941544L (no) Rekombinant kjerne-streptavidin

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee
8364 No opposition during term of opposition